Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
D Planchard, S Popat, K Kerr, S Novello… - Annals of …, 2019 - annalsofoncology.org
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
H Horinouchi, N Nogami, H Saka, M Nishio… - Cancer …, 2021 - Wiley Online Library
Pembrolizumab plus pemetrexed‐platinum significantly improved overall survival (OS) and
progression‐free survival (PFS) with manageable safety compared with placebo plus …
progression‐free survival (PFS) with manageable safety compared with placebo plus …
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label …
CJ Langer, SM Gadgeel, H Borghaei… - The lancet …, 2016 - thelancet.com
Background Limited evidence exists to show that adding a third agent to platinum-doublet
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …
FP13. 02 pembrolizumab+ pemetrexed-platinum vs pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189
J Gray, D Rodríguez-Abreu, SF Powell… - Journal of Thoracic …, 2021 - jto.org
Methods Patients were randomized (2: 1) to intravenous pembrolizumab 200 mg or placebo
Q3W for up to 35 cycles (2 years). All patients received pemetrexed and investigator's choice …
Q3W for up to 35 cycles (2 years). All patients received pemetrexed and investigator's choice …
[HTML][HTML] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final …
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - Annals of …, 2021 - Elsevier
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non …
MC Garassino, S Gadgeel, E Esteban, E Felip… - The Lancet …, 2020 - thelancet.com
Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and
progression-free survival, and a higher proportion of patients with a confirmed complete or …
progression-free survival, and a higher proportion of patients with a confirmed complete or …
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell …
S Gadgeel, D Rodríguez-Abreu, G Speranza… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
OA05. 07 IMpower132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin+ pemetrexed in stage IV non-squamous NSCLC
V Papadimitrakopoulou, M Cobo, R Bordoni… - Journal of Thoracic …, 2018 - jto.org
Background In addition to the combination of atezolizumab (anti–PD-L1)+ platinum+
taxane±bevacizumab, non-squamous NSCLC patients may derive benefit from adding …
taxane±bevacizumab, non-squamous NSCLC patients may derive benefit from adding …